Sign in
CompletedNo phase

HCV and Co-morbid Alcohol Use Disorders: A Translational Investigation of Antiviral Therapy Outcomes on CNS Function

Key facts

Who runs it
VA Office of Research and Development
Where
Portland, United StatesSee the site
Trial code
Status
Completed
People taking part
63 people enrolled
Started
16 May 2019
Ended
29 Dec 2023
Type of study
Observational, 4 groups
Treatments tested
  • Neuropsychological assessment
  • Neuroimaging
Record updated
27 March 2025

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Can take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Adult Veteran (>21 years)
  • Able to provide informed consent

Who cannot take part

  • Contraindications to MRI (such as surgical aneurysm clips, pacemaker, prosthetic heart valve, neuro-stimulator, implanted pumps, cochlear implants, metal rods, plates or screws, previous surgery, hearing aids, history of welding, metal shrapnel)
  • Current substance use disorder other than alcohol (except nicotine or caffeine)
  • Medical conditions likely to impact immunological function or central nervous system function (such as HIV, cancer, lupus, stroke, neurodegenerative disease, hepatic encephalopathy, multiple sclerosis, or a traumatic brain injury)
  • Past or present schizophrenia, schizoaffective disorder, or current psychosis or mania
  • Visible intoxication or impaired capacity to understand study risks and benefits or otherwise provide informed consent
  • Visual or auditory impairments that would prevent valid neuropsychiatric testing

Where in United States

  • VA Portland Health Care System, Portland, ORPortland, United States

About the trial

What the trial wants to find out

The primary objective of this research project is to compare neuropsychiatric functioning, cortical activity, white matter integrity, and immune response among Veterans with and without alcohol use disorder (AUD), before and after direct-acting antiviral (DAA) therapy [a new treatment for chronic infection with the hepatitis C virus (HCV)]. Demographically-matched comparison groups of Veterans without HCV (HCV-, with and without AUD) will similarly be evaluated to determine the relative contribution of HCV and an HCV "cure" to outcomes putatively affected by alcohol abuse.

Read full original descriptionShow less

Two specific aims are proposed.

Aim 1: Determine the impact of DAA therapy and a sustained viral response on central nervous system (CNS) function.

Aim 2: Evaluate the effects of AUD and unhealthy alcohol drinking on DAA therapy outcomes and CNS function.

The information learned will address a critical gap in knowledge concerning the effects of alcohol use on DAA therapy outcomes and will help inform treatment guidelines that could be translated to clinical practice, such as targeted interventions to treat AUD in conjunction with HCV infection and follow-up strategies for patients who successfully complete DAA therapy but then need care for other potential CNS-related outcomes.

The 4 groups in the trial

  • AUD+/HCV+

    * With current Alcohol Use Disorder and with HCV * About to initiate DAA therapy for HCV

    Treatment: Neuropsychological assessment and Neuroimaging

  • AUD-/HCV+

    * Without current Alcohol Use Disorder and with HCV * About to initiate DAA therapy for HCV

    Treatment: Neuropsychological assessment and Neuroimaging

  • AUD+/HCV-

    -With Alcohol Use Disorder and without HCV

    Treatment: Neuropsychological assessment and Neuroimaging

  • AUD-/HCV-

    -Without Alcohol Use Disorder and without HCV

    Treatment: Neuropsychological assessment and Neuroimaging

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
27 March 2025